PELLEGRINI, CAROLINA
 Distribuzione geografica
Continente #
NA - Nord America 3.275
EU - Europa 1.966
AS - Asia 502
AF - Africa 119
SA - Sud America 15
OC - Oceania 1
Totale 5.878
Nazione #
US - Stati Uniti d'America 3.224
IT - Italia 988
SE - Svezia 291
CN - Cina 185
BG - Bulgaria 160
AT - Austria 142
DE - Germania 102
SG - Singapore 95
VN - Vietnam 89
GB - Regno Unito 76
CI - Costa d'Avorio 69
RU - Federazione Russa 56
CA - Canada 43
SN - Senegal 36
HK - Hong Kong 34
PL - Polonia 31
IN - India 29
FR - Francia 28
BE - Belgio 27
IR - Iran 21
FI - Finlandia 17
UA - Ucraina 15
JP - Giappone 13
BR - Brasile 12
TR - Turchia 12
CH - Svizzera 9
KR - Corea 7
MX - Messico 7
NG - Nigeria 6
ES - Italia 5
PK - Pakistan 5
GH - Ghana 3
IE - Irlanda 3
LB - Libano 3
NL - Olanda 3
PT - Portogallo 3
RO - Romania 3
HU - Ungheria 2
MO - Macao, regione amministrativa speciale della Cina 2
NO - Norvegia 2
PH - Filippine 2
UG - Uganda 2
AU - Australia 1
AZ - Azerbaigian 1
BD - Bangladesh 1
CL - Cile 1
CO - Colombia 1
CU - Cuba 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DZ - Algeria 1
EC - Ecuador 1
ID - Indonesia 1
MA - Marocco 1
MK - Macedonia 1
MY - Malesia 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 5.878
Città #
Fairfield 482
Woodbridge 329
Ashburn 295
Chandler 292
Houston 224
Seattle 203
Milan 180
Wilmington 169
Cambridge 167
Sofia 160
Serra 157
Ann Arbor 139
New York 135
Vienna 101
Pisa 99
Beijing 87
Princeton 79
Abidjan 69
Lawrence 62
Florence 57
Bremen 48
Dong Ket 48
Medford 48
Rome 43
Dakar 36
Des Moines 36
Ottawa 36
Hong Kong 32
London 31
Brussels 26
Dearborn 25
Nanjing 24
Redwood City 22
Warsaw 19
Pistoia 18
Frankfurt am Main 17
Marseille 14
Washington 14
Livorno 13
San Diego 13
Bologna 12
Phoenix 10
Izmir 9
Nanchang 9
Lancaster 8
Padova 8
Palermo 8
Aguascalientes 7
Lucca 7
Montecatini Terme 7
Turin 7
Ancona 6
Boardman 6
Changsha 6
Kunming 6
Lagos 6
Redmond 6
Chicago 5
Columbus 5
Norwalk 5
Parma 5
Pune 5
Singapore 5
Tagliacozzo 5
Apucarana 4
Atlanta 4
Ballabio 4
Boulder 4
Busto Arsizio 4
Guangzhou 4
Haikou 4
Hebei 4
Hefei 4
Jacksonville 4
Jiaxing 4
Naples 4
Toronto 4
Beirut 3
Carrara 3
Dallas 3
Dublin 3
Duque de Caxias 3
Fremont 3
Kolkata 3
Massa 3
Porto 3
Rochester 3
Seoul 3
Shenyang 3
Shenzhen 3
Tianjin 3
Verona 3
Vijayawada 3
Wuhan 3
Żyrardów 3
Acquafredda 2
Auburn Hills 2
Avellino 2
Barrea 2
Bergamo 2
Totale 4.328
Nome #
Protective Role of Flavonoids Against Colonic Motor Dysfunctions Associated with High Fat Diet-Induced Obesity 176
COMPOSTI INIBITORI DELL’INFLAMMASOMA NLRP3 E LORO USO 154
Enteric protective effects of the combination Bifidobacterium longum and lactoferrin in a rat model of diclofenac-induced intestinal injury. 140
Pathophysiology of NSAID-associated intestinal lesions in the rat: Luminal bacteria and mucosal inflammation as targets for prevention 139
Histochemical Detection of Collagen Fibers by Sirius Red/Fast Green Is More Sensitive than van Gieson or Sirius Red Alone in Normal and Inflamed Rat Colon 136
Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic 135
Colonic motor dysfunctions in a mouse model of high-fat diet-induced obesity: an involvement of A2B adenosine receptors 132
NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same? 131
Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 130
The AMPK enzyme-complex: from the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders 124
Canonical and Non-Canonical Activation of NLRP3 Inflammasome at the Crossroad between Immune Tolerance and Intestinal Inflammation 120
Involvement of the P2X7 purinergic receptor in colonic motor dysfunction associated with bowel inflammation in rats 117
The flavonoid compound apigenin prevents colonic inflammation and motor dysfunctions associated with high fat diet-induced obesity 116
A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation 116
Enteric dysfunctions in experimental Parkinson's disease: alterations of excitatory cholinergic neurotransmission regulating colonic motility in rats 114
Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients 113
Colonic dysmotility associated with high-fat diet-induced obesity: Role of enteric glia 110
The role of purinergic pathways in the pathophysiology of gut diseases: pharmacological modulation and potential therapeutic applications 109
USP7 and USP47 deubiquitinases regulate NLRP3 inflammasome activation 105
Prodromal Intestinal Events in Alzheimer's Disease (AD): Colonic Dysmotility and Inflammation Are Associated with Enteric AD-Related Protein Deposition 105
Intestinal dysfunction in Parkinson's disease: Lessons learned from translational studies and experimental models 103
Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease 102
AMPK Activators as Novel Drug Candidates for the Treatment of Inflammatory Bowel Diseases 102
Mechanisms underlying the non-anticoagulant effects of apixaban and dabigatran on the integrity of intestinal mucosa: a comparative pre-clinical study. 101
High Levels of β-Amyloid, Tau, and Phospho-Tau in Red Blood Cells as Biomarkers of Neuropathology in Senescence-Accelerated Mouse 101
Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications? 101
Protective effects of the combination Bifidobacterium longum plus lactoferrin against NSAID-induced enteropathy 100
Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases? 94
null 94
Luteolin Prevents Cardiometabolic Alterations and Vascular Dysfunction in Mice With HFD-Induced Obesity 90
Dietary flavonoids as a potential intervention to improve redox balance in obesity and related co-morbidities: a review 88
Rifaximin Displays a Protective Activity in Experimental Enteropathy Induced by Indomethacin in Rats. 87
P2X7 receptor-dependent tuning of gut epithelial responses to infection 85
Interplay between colonic inflammation and tachykininergic pathways in the onset of colonic dysmotility in a mouse model of diet-induced obesity 84
Anti-inflammatory Effects of Novel P2X4 Receptor Antagonists, NC-2600 and NP-1815-PX, in a Murine Model of Colitis 84
Role of the A(2B) receptor-adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rat 81
Constipation, deficit in colon contractions and alpha-synuclein inclusions within the colon precede motor abnormalities and neurodegeneration in the central nervous system in a mouse model of alpha-synucleinopathy 81
null 80
The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis 80
The administration of Enterococcus faecium SF68 counteracts compositional shifts in the gut microbiota of diet-induced obese mice 78
Preclinical development of fa5, a novel amp-activated protein kinase (Ampk) activator as an innovative drug for the management of bowel inflammation 77
Glial A2B Adenosine Receptors Modulate Abnormal Tachykininergic Responses and Prevent Enteric Inflammation Associated with High Fat Diet-Induced Obesity 76
Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology 69
Phytochemicals as Novel Therapeutic Strategies for NLRP3 Inflammasome-Related Neurological, Metabolic, and Inflammatory Diseases 68
Adenosine signaling in the tumor microenvironment 67
Neuronal regulation of intestinal immune functions in health and disease 66
Differential Impact of Weight Loss and Glycemic Control on Inflammasome Signaling 64
Palmitoylethanolamide Counteracts Enteric Inflammation and Bowel Motor Dysfunctions in a Mouse Model of Alzheimer’s Disease 64
NLRP3 at the crossroads between immune/inflammatory responses and enteric neuroplastic remodelling in a mouse model of diet-induced obesity 64
Dietary Supplement, Containing the Dry Extract of Curcumin, Emblica and Cassia, Counteracts Intestinal Inflammation and Enteric Dysmotility Associated with Obesity 62
Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration 62
Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence 59
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 57
Donepezil improves vascular function in a mouse model of Alzheimer's disease 54
- Medicament for preventing or treating irritable bowel syndrome or inflammatory bowel diseases 53
Opioid receptors beyond pain control: The role in cancer pathology and the debated importance of their pharmacological modulation 52
Intestinal epithelial barrier and neuromuscular compartment in health and disease 51
Deepening the Mechanisms of Visceral Pain Persistence: An Evaluation of the Gut-Spinal Cord Relationship 50
The adenosine system at the crossroads of intestinal inflammation and neoplasia 49
Managing Obesity and Related Comorbidities: A Potential Pharmacological Target in the Adenosine System? 49
From the intestinal mucosal barrier to the enteric neuromuscular compartment: an integrated overview on the morphological changes in Parkinson's disease 47
Role of proteinase-activated receptors 1 and 2 in nonsteroidal anti-inflammatory drug enteropathy 43
Enteric glia at the crossroads between intestinal immune system and epithelial barrier: Implications for parkinson disease 39
Protective effects of Saccharomyces boulardii CNCM I-745 Against Nonsteroidal anti-inflammatory drug-induced intestinal injury 38
Inflammatory Bowel Diseases: It's Time for the Adenosine System 37
NKG2A and COVID-19: another brick in the wall 36
Ectopic Lymphoid Organs and Immune-Mediated Diseases: Molecular Basis for Pharmacological Approaches 36
Anti-inflammatory effect of a novel locally acting A2A receptor agonist in a rat model of oxazolone-induced colitis. 35
NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications 32
Editorial: IBD Management—Novel Targets and Therapeutic Perspectives 31
Dietary Supplementation with the Probiotic SF68 Reinforces Intestinal Epithelial Barrier in Obese Mice by Improving Butyrate Bioavailability 29
Intestinal histomorphological and molecular alterations in patients with Parkinson's disease 26
Intestinal histomorphological and molecular alterations in patients with Parkinson's disease 25
Role of cyclooxygenase pathways in bowel fibrotic remodelling in a murine model of experimental colitis 24
LRRK2 is reduced in Parkinson’s disease gut 24
Enteric Glia and Brain Astroglia: Complex Communication in Health and Disease along the Gut-Brain Axis 21
Glomerular hyperfiltration in morbid obesity: Role of the inflammasome signalling 17
Use of Saccharomyces boulardii CNCM I-745 as therapeutic strategy for prevention of nonsteroidal anti-inflammatory drug-induced intestinal injury 12
Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 12
The intestinal barrier in disorders of the central nervous system 11
Pharmacological modulation of P2X4 in inflammatory bowel diseases: the way towards novel therapeutics? 10
Adenosine signaling as target in cardiovascular pharmacology 7
LRRK2 expression in normal and pathologic human gut and in rodent enteric neural cell lines 6
Velusetrag rescues GI dysfunction, gut inflammation and dysbiosis in a mouse model of Parkinson's disease 4
Pathological Remodeling of the Gut Barrier as a Prodromal Event of High-Fat Diet-Induced Obesity 4
Author Correction: Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology (npj Parkinson's Disease, (2022), 8, 1, (9), 10.1038/s41531-021-00263-x) 4
Neuromuscular Function Abnormalities 3
Editorial: Neurological, Metabolic and Inflammatory Disorders: A Common Root in Inflammasome 1
Are LRRK2 mysteries lurking in the gut? 1
Totale 6.166
Categoria #
all - tutte 17.745
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.745


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019305 0 0 0 0 0 0 0 0 11 64 127 103
2019/20201.149 90 59 26 95 120 137 121 105 157 89 115 35
2020/2021765 61 61 67 32 43 33 31 53 102 119 39 124
2021/2022759 27 16 18 25 146 113 41 36 62 46 49 180
2022/20231.367 133 164 96 101 122 150 38 125 240 53 104 41
2023/20241.071 110 121 175 108 194 225 54 84 0 0 0 0
Totale 6.166